Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus | Zendy

Jorge E. Toblli | Zendy; Mónica G. Ferrini | Zendy; Guoliang Cao | Zendy; Dolores Vernet | Zendy; Margarita Angerosa | Zendy; Néstor F. González-Cadavid | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus

Author(s) -

Jorge E. Toblli,

Mónica G. Ferrini,

Guoliang Cao,

Dolores Vernet,

Margarita Angerosa,

Néstor F. González-Cadavid

Publication year - 2009

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfp103

Subject(s) - medicine , endocrinology , pioglitazone , glomerulosclerosis , fibrosis , kidney , renal function , creatinine , oxidative stress , proteinuria , diabetes mellitus , type 2 diabetes , inflammation

Recent evidence suggests that treatment of type 2 diabetes with thiazolidinediones [peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists], ameliorates glomerulosclerosis and tubulointerstitial fibrosis in the rat kidney. In the current work, we have investigated whether these drugs, and specifically pioglitazone (PGT), act by preventing fibrosis and kidney dysfunction mainly through antioxidant and anti-inflammatory effects, independently of glycaemic control.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research